CoChat

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Background: Novel and effective immunotherapies are required for refractory or recurrent sarcomas. Transforming growth factor-beta (TGF-β) is a diverse regulatory and fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition and excessive deposition of extracellular matrix. This study evaluated the efficacy and safety of the anti-PD-L1/TGF-β antibody TQB2858 in patients with refractory osteosarcoma and alveolar soft part sarcoma (ASPS). Methods: This single-arm phase 1b exploratory study included patients with refractory osteosarcoma or ASPS who had previously undergone at least two lines of systemic therapy. Patients were administered 1200 mg of TQB2858 once every 3 weeks. The primary endpoint was objective response rate (ORR), with null and alternative hypotheses of ORR ≤5% and ≥20%, respectively. Exploratory biomarker analyses using immunohistochemistry (IHC) staining (for PD-L1 and TGF-β) were performed on pre-treatment tumor samples. Results: Eleven eligible patients were included in this study. TQB2858 did not demonstrate evidence of efficacy as 0/5 osteosarcomas had any objective response, while 2/6 ASPS showed a partial response. The median progression-free survivals were 1.51 (1.38, Not Evaluable) and 2.86 (1.38, Not Evaluable) months for the osteosarcoma and ASPS groups, respectively. None of the administered cycles met the criteria for unacceptable toxicity. Other Grade 3 toxicities included abnormal liver function and elevation of γ-glutamyl transferase. IHC analysis revealed that functional enrichment in the TGF-β pathway or PD-L1 was not associated with treatment outcomes. Conclusions: The combination of PD-L1 and TQB2858 did not significantly improve the ORR in patients with recurrent osteosarcoma. However, it improved immunogenic responses in ASPS, even after progression upon anti-PD-1/PD-L1 therapy, with an acceptable safety profile. IHC profiling with pathway enrichment analysis may not have any predictive value for survival outcomes. Trial registration: Prospectively registered in the Ethical Review Committee of Peking University People’s Hospital. The trial registration number is 2021PHA105-001 and 2021PHA140-001 and the registration date was March 2, 2022. ClinicalTrials.gov Identifier CTR20213001 and CTR20220390

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-023-11390-4

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Kaplan–Meier curves for PFS. ASPS, alveolar soft part sarcoma. PFS, progression free survival
Fig. 1 Kaplan–Meier curves for PFS. ASPS, alveolar soft part sarcoma. PFS, progression free survivalCC BY · PubMed Central
Fig. 2 Waterfall plot for best percentage change in target lesion size in FAS. ASPS, alveolar soft part sarcoma. PD, progressive disease; SD, stable disease; PR, partial response; FAS, full analysis set
Fig. 2 Waterfall plot for best percentage change in target lesion size in FAS. ASPS, alveolar soft part sarcoma. PD, progressive disease; SD, stable disease; PR, partial response; FAS, full analysis setCC BY · PubMed Central
Fig. 3 Spider plot for best percentage change in target lesion size in FAS. ASPS, alveolar soft part sarcoma. PD, progressive disease; SD, stable disease; PR, partial response; FAS, full analysis set
Fig. 3 Spider plot for best percentage change in target lesion size in FAS. ASPS, alveolar soft part sarcoma. PD, progressive disease; SD, stable disease; PR, partial response; FAS, full analysis setCC BY · PubMed Central
Fig. 4 Radiological changes for the patient (PR) with metastatic alveolar soft part sarcoma. A, B Before treatment computerized tomography (CT) scans of target lesions in the lung site. C, D After treatment CT scans of target lesions in the lung site
Fig. 4 Radiological changes for the patient (PR) with metastatic alveolar soft part sarcoma. A, B Before treatment computerized tomography (CT) scans of target lesions in the lung site. C, D After treatment CT scans of target lesions in the lung siteCC BY · PubMed Central
Fig. 5 IHC staining of tumor biospecimens. A, B IHC staining of PD-L1 and TGF-β in patient 01007. C, D IHC staining of PD-L1 and TGF-β in patient 01010. E, F IHC staining of PD-L1 and TGF-β in patient 01002. IHC, immumohistochemical staining. PD-L1, programmed cell death ligand 1; TGF-β, transforming growth factor-beta
Fig. 5 IHC staining of tumor biospecimens. A, B IHC staining of PD-L1 and TGF-β in patient 01007. C, D IHC staining of PD-L1 and TGF-β in patient 01010. E, F IHC staining of PD-L1 and TGF-β in patient 01002. IHC, immumohistochemical staining. PD-L1, programmed cell death ligand 1; TGF-β, transforming growth factor-betaCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 18

Metadata

Authors
Xie, L., Liang, X., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Tang, X., Li, X., Zhan, X., Niu, X., & Guo, W.
Affiliations
  • Peking University People's Hospital (CN)
  • Hunan Cancer Hospital (CN)
  • Sun Yat-sen University Cancer Center (CN)
  • Beijing Jishuitan Hospital (CN)
Corresponding author
  • Tang, Xiaodong
  • Guo, Wei
Venue
BMC Cancer
Published
2023-09-15
Volume
23
Issue
1
Pages
868-868
ISSN
1471-2407 (ISSN-L)
OpenAlex
W4386780127
Cited by
14
References
30
Citations by year
2026: 4 · 2025: 7 · 2024: 2 · 2023: 1
FWCI
2.57
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the Research and Development Fund of Peking University People’s Hospital (Clinical Research and Cultivation Program, grant no. RDL2022-37)
  • Chia Tai TianQing Pharmaceutical Group Co., Ltd. (TQB2858-Ib-02)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
osteosarcoma, alveolar soft part sarcoma, refractory sarcoma, recurrent sarcoma, PD-L1, TGF-beta, immune checkpoint inhibitors, objective response rate, immunotherapy safety, predictive biomarkers, PD-1/PD-L1 blockade
MeSH terms
Antineoplastic Agents, Immunological, East Asian People, Antibodies, Bone Neoplasms, Humans, Osteosarcoma, Soft Tissue Neoplasms, Transforming Growth Factor beta, Sarcoma, Alveolar Soft Part, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02). https://app.cochat.ai/papers/10.1186/s12885-023-11390-4
The paper
Xie, L., Liang, X., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Tang, X., Li, X., Zhan, X., Niu, X., & Guo, W. (2023). Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02). BMC Cancer. https://doi.org/10.1186/s12885-023-11390-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.